2019

De Francesco, D., Winston, A., Underwood, J., Cresswell, F.V., Anderson, J., Post, F.A., ...Babalis, D. (2019). Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. International Journal of STD and AIDS, doi:10.1177/0956462418817612
De Francesco, D., Underwood, J., Bagkeris, E., Boffito, M., Post, F.A., Mallon, P., ...Johnson, M. (2019). Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls.. HIV Med, doi:10.1111/hiv.12714
Manmathan, G.P.R., Chacko, L., Murki, R., Kotecha, T., Brown, J., Little, C., ...Kinloch, S. (2019). Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI).
Van Hecke, C., Trypsteen, W., Malatinkova, E., De Spiegelaere, W., Vervisch, K., Rutsaert, S., ...Vandekerckhove, L. (2019). Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors. EBIOMEDICINE, 41 443-454. doi:10.1016/j.ebiom.2019.02.006
Psomas, C.K., Philibert, P., Kinloch, S. (2019). Highlights from HIV Glasgow 28-31 October 2018 Glasgow, UK. JOURNAL OF VIRUS ERADICATION, 5 (1), 67-72.
Psomas, C.K., Waters, L., Barber, T., Fidler, S., Macartney, M., Alagaratnam, J., ...Kinloch, S. (2019). Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science, 21-25 July 2019, Mexico City, Mexico. JOURNAL OF VIRUS ERADICATION, 5 (4), 245-252.
Psomas, C.K., Kinloch, S. (2019). Highlights of the Conference on Retroviruses and Opportunistic Infections, 4-9 March 2019, Seattle, WA, USA.. Journal of virus eradication, 5 (2), 125-131.
Manmathan, G., Little, C., Ngwu, N., Kotecha, T., Hunter, A., Johnson, M., ...Rakhit, R. (2019). Impact of application of new American hypertension guidelines to a UK HIV cohort.
Dhillon, S., Sabin, C.A., Alagaratnam, J., Bagkeris, E., Post, F.A., Boffito, M., ...Johnson, M. (2019). Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. HIV Medicine, doi:10.1111/hiv.12731
Manmathan, G.P.R., Kotecha, T., Chacko, L., Brown, J., Little, C., Knight, D., ...Burns, F. (2019). Myocardial abnormalities in people living with Human Immunodeficiency Virus (PLWH) detected using cardiovascular magnetic resonance (CMR).
Alagaratnam, J., Stohr, W., Toombes, J., Zetterberg, H., Pett, S., Nelson, M., ...Johnson, M. (2019). No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial.
Manmathan, G., Ramphul, R., Little, C., Kotecha, T., Hunter, A., Hemat, N., ...Rakhit, R. (2019). Reclassification of renal failure using modified KDIGO classification and comparison between a UK versus Japanese HIV cohort.
De Francesco, D., Underwood, J., Bagkeris, E., Anderson, J., Williams, I., Vera, J.H., ...Mallon, P.W.G. (2019). Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV.. AIDS, doi:10.1097/QAD.0000000000002293
Copelyn, J., Thompson, L.C., Le Prevost, M., Castro, H., Sturgeon, K., Rowson, K., ...Judd, A. (2019). Self-harm in young people with perinatal HIV and HIV negative young people in England: cross sectional analysis.. BMC Public Health, 19 (1), 1165. doi:10.1186/s12889-019-7424-7
Johnson, M., Kinloch-de Loes, S. (2019). Untitled. JOURNAL OF VIRUS ERADICATION, 5 (4), I.
Gossez, M., Martin, G.E., Pace, M., Ramjee, G., Premraj, A., Kaleebu, P., ...Meyerowitz, J. (2019). Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.. AIDS, doi:10.1097/QAD.0000000000002044
Manmathan, G., Kotecha, T., Little, C., Ngwu, N., Hunter, A., Burns, F., ...Rakhit, R. (2019). Waist: hip ratio (WHR): a better predictor of cardiovascular risk (CVR) than body mass index (BMI) in people living with HIV (PLWH).
Manmathan, G.P.R., Little, C., Kotecha, T., Ngwu, N., Hunter, A., Kinloch, S., ...Rakhit, R.D. (2019). Waist:Hip ratio (WHR): a better predictor of cardiovascular risk (CVR) than BMI in people living with HIV.

2018

Fidler, S., Stohr, W., Pace, M., Dorrell, L., Lever, A., Pett, S., ...Nelson, M. (2018). A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a "Kick-and-Kill" approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial.
Xu, L., Zhu, B., Huang, Y., Yang, Z., Sun, J., Xu, Y., ...Weng, H. (2018). Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients. MEDIATORS OF INFLAMMATION, doi:10.1155/2018/5201652
Psomas, C., Kinloch, S., Sabin, C., Soriano, V., Solas, C., Orkin, C., ...Enel, P. (2018). Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health. Journal of Virus Eradication, 4 (3), 196-207.
Psomas, C.K., Fidler, S., Macartney, M., Jeffreys, R., Reilly, L., Collins, S., ...Kinloch-de Loes, S. (2018). Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam , the Netherlands. JOURNAL OF VIRUS ERADICATION, 4 (4), 238-247.
Pool, E.R.M., Winston, A., Bagkeris, E., Vera, J.H., Mallon, P.W.G., Sachikonye, M., ...Anderson, J. (2018). High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men. HIV Medicine, doi:10.1111/hiv.12690
Francesco, D.D., Verboeket, S.O., Underwood, J., Bagkeris, E., Wit, F.W., Mallon, P.W.G., ...Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort, S.t.u.d.y. (2018). Patterns of Co-occurring Comorbidities in People Living With HIV.. Open Forum Infect Dis, 5 (11), ofy272. doi:10.1093/ofid/ofy272
Katiyar, A., Gathogo, E., Kinloch-de Loes, S., Johnson, M., Lampe, F., Smith, C.J. (2018). Rate of HIV rebound and CD4 T cell kinetics in an ageing population on successful antiretroviral therapy.
Thornhill, J., Hoare, J., Peake, S., Khan, M., Williamson, K., Murray, C., ...Fidler, S. (2018). Two case reports on safety and impact of alpha 4 beta 7 integrin monoclonal antibody in treated primary HIV infection on HIV reservoirs OVERRIDE.

2017

McLean, F.E., Gathogo, E., Goodall, D., Jones, R., Kinloch, S., Post, F.A. (2017). Alemtuzumab induction therapy in HIV-positive renal transplant recipients. AIDS, doi:10.1097/QAD.0000000000001413
Wu, N., Malatinkova, E., Laufs, S., Zahn, M., de Spiegelaere, W., Afzal, S., ...Vandekerckhove, L. (2017). Exploring the Influence of HIV-1 Integration in Different Tissues: Blood and Gut.
Crowell, T.A., Lyall, H., Malatinkova, E., Bhagani, S., Hsu, D., Colby, D.J., ...Gathogo, E.N. (2017). Highlights from the 24th Conference on Retroviruses and Opportunistic Infections: 13-16 February 2017, Seattle, Washington, USA.. Journal of virus eradication, 3 (2), 101-108.
Psomas, C.K., Barber, T.J., Rutsaert, S., Kinloch-de Loës, S. (2017). Highlights from the 9th IAS Conference on HIV Science, 23-26 July 2017, Paris, France.. Journal of virus eradication, 3 (4), 242-249.

2016

Marshall, N., Swaden, L., Katiyar, A., Hunter, A., Tsintas, R., Bhagani, S., ...Lipman, M. (2016). Clinical outcomes of co-prescription of ranitidine with boosted atazanavir and rilpivirine-based ART.
Martin, G.E., Pantazis, N., Hoffmann, M., Hickling, S., Hurst, J., Meyerowitz, J., ...Fisher, M. (2016). Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection.
Babiker, A., Hoffmann, M., Pantazis, N. (2016). Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection.. PLoS Pathog, doi:10.1371/journal.ppat.1005661
Hamlyn, E., Stoehr, W., Porter, K., Parmer, K., Hunt, B.J., Kinloch, S., ...Fidler, S. (2016). Inflammation and microbial translocation in primary HIV infection and the effect of short-course antiretroviral therapy.
Van Schalkwyk, M., Westbrook, R.H., O'Beirne, J., Wright, A., Gonzalez, A., Johnson, M.A., Kinloch-de Loës, S. (2016). Twin pregnancy in a liver transplant recipient with HIV infection.. Journal of virus eradication, 2 (4), 232-234.

2015

Kinloch-de Loes, S., Dorrell, L., Yang, H., Hardy, G.A.D., Yerly, S., Cellerai, C., ...Koh, W.W.L. (2015). Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses. OPEN FORUM INFECTIOUS DISEASES, 2 (4), doi:10.1093/ofid/ofv144
Kinloch, S., Johnson, M., Yang, H., Dorrell, L., Vandekerckhove, L., Malatinkova, E., ...Webster, D. (2015). Aviremia 10-year post-ART discontinuation initiated at seroconversion. HIV MEDICINE, 16 21.
Fidler, D., Hall, M., Madge, S., Kinloch, S., Grover, D., Johnson, M., ...Speakman, A. (2015). Bone mineral density assessed by DEXA (Dual-Energy X-ray Absorptiometry) scans of HIV-positive people attending a large HIV centre.
Kinloch, S., Kwong, T.-.S., Ellis, J., Johnson, M., Smith, C. (2015). Enhanced immune reconstitution with initiation of ART at HIV-1 seroconversion (PHI).
Hurst, J., Hoffmann, M., Pace, M., Williams, J.P., Thornhill, J., Hamlyn, E., ...Robinson, N. (2015). Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. NATURE COMMUNICATIONS, 6 doi:10.1038/ncomms9495
Malatinkova, E., De Spiegelaere, W., Bonczkowski, P., Kiselinova, M., Vervisch, K., Trypsteen, W., ...Murray, C. (2015). Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. ELIFE, 4 doi:10.7554/eLife.09115
Kinloch-de Loës, S., Brown, C.S. (2015). International Congress on Targeting Ebola: 28-29 May 2015, Pasteur Institute, Paris.. Journal of virus eradication, 1 (4), 282-283.
Koganti, S., Kinloch-de Loes, S., Hutchinson, S., Johnson, M., Rakhit, R.D. (2015). Management of cardiovascular conditions in a cohort of patients with HIV: experience from a joint HIV/cardiology clinic. CLINICAL MEDICINE, 15 (5), 442-446. doi:10.7861/clinmedicine.15-5-442

2014

Brima, N., Lampe, F., Smith, C., Phillips, A., Copas, A., Gilson, R., ...Burns, F. (2014). Early virological response to antiretroviral therapy: can we predict earlier who is unlikely to achieve a response at 6 months?.
Lafeuillade, A., Wainberg, M., Gougeon, M.-.L., Kinloch-de Loes, S., Halfon, P., Tissot-Dupont, H. (2014). Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic. AIDS RESEARCH AND THERAPY, 11 doi:10.1186/1742-6405-11-28
Williams, J.P., Hurst, J., Stöhr, W., Robinson, N., Brown, H., Fisher, M., ...Tambussi, G. (2014). HIV-1 DNA predicts disease progression and post-treatment virological control.. ELIFE, 3 doi:10.7554/eLife.03821

2013

Geretti, A.M., Arribas, J.R., Lathouwers, E., Foster, G.M., Yakoob, R., Kinloch, S., ...Moecklinghoff, C. (2013). Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.. HIV CLINICAL TRIALS, 14 (1), 45-50. doi:10.1310/hct1401-45
Dore, G., Kinloch, S., Rodríguez-Baño, J., Shingadia, D. (2013). Editorial.. Therapeutic advances in infectious disease, 1 (1), 3-. doi:10.1177/2049936113477643
SPARTAC Trial, I.n.v.e.s.t.i.g.a.t.o.r.s., Fidler, S., Porter, K., Ewings, F., Frater, J., Ramjee, G., ...Schechter, M. (2013). Short-course antiretroviral therapy in primary HIV infection.. NEW ENGLAND JOURNAL OF MEDICINE, 368 (3), 207-217. doi:10.1056/NEJMoa1110039

2012

Kinloch, S., Reynold, S.J., Bollinger, R.C. (2012). Acute HIV Infection. In Gupta, S., Kumar, B. (Eds.), Sexually Transmitted Infections. (pp. 843-848). Elsevier India Pvt. Ltd.
Geretti, A.M., Arribas, J.R., Vingerhoets, J., Foster, G., Kinloch, S., Hill, A., ...Moecklinghoff, C. (2012). Brief report: Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. HIV Clinical Trials, In press
Smith, C., Lampe, F., Chaloner, C., Kinloch, S., Tsintas, R., Madge, S., ...Johnson, M. (2012). Continued improvements in clinical outcomes in the current ART era: epidemiology of a complete clinic population.
Smith, C.J., Phillips, A.N., Kinloch, S., Lipman, M.C.I., Lodwick, R.K., Tyrer, M., ...Lampe, F.C. (2012). Frequency of treatment interruptions over calendar time: The impact of results from the SMART study. Antiviral Therapy, Submitted
Kojeku, A., Handrahan, C., Wight, A., Levit, D., Marshall, N., Johnson, M., ...Kinloch, S. (2012). Normalising childbirth in women living with HIV: a London teaching hospital experience.
Kinloch, S. (2012). Primary HIV Infection. Plenary.
SPARTAC Trial, I.n.v.e.s.t.i.g.a.t.o.r.s., Kinloch, S. (2012). The effect of short course antiretroviral therapy in primary HIV infection: final results from SPARTAC, an international randomized controlled trial. New England Journal of Medicine, In press

2011

Kinloch, S., Geretti, A.M. (2011). Chasing the Infecting HIV-1. Clin Infect Dis, 53 (12), 1280-1282.
Cellerai, C., Yerly, S., Gougeon, M.L., Johnson, M.A., Geretti, A.M., Carroll, A., Kinloch, S. (2011). Discontinuation of long-term ART initiated at seroconversion can be associated with prolonged high viremia and preservation of CD4 cells - abstract.
Cellerai, C., Harari, A., Stauss, H., Yerly, S., Geretti, A.M., Carroll, A., ...Sweeney, J. (2011). Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. PLOS ONE, 6 (4), doi:10.1371/journal.pone.0018164
Cellerai, C., Harari, A., Stauss, H., Yerly, S., Geretti, A.M., Carroll, A., ...Sweeney, J. (2011). Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One, 6 (4), e18164-.
Kinloch, S., Cellerai, C. (2011). HIV and the immune system. In Rodger, A.J., Mahungu, T.W., Johnson, M.A. (Eds.), HIV/AIDS: An Atlas of Investigation and Management. Clinical Publishing.
Kinloch, S. (2011). Primary HIV infection an update. HIV Academic meeting, Department of Infectious Diseases.
Kinloch, S. (2011). Prolonged antiretroviral therapy initiated at seroconversion is associated with a polyfunctional HIV-1 specific T-cell profile comparable to that of long-term non-progressors (LTNPS). Oral presentation. [abstract 029].
Cellerai, C., Harari, A., Stauss, H., Yerly, S., Geretti, A.M., Carroll, A., ...Sweeney, J. (2011). Prolonged antiretroviral therapy initiated at seroconversion is associated with a polyfunctional HIV-1-specific T-cell profile comparable to that of long-term non-progressors (LTNPs). HIV MEDICINE, 12 11.
Kinloch, S. (2011). T cell responses in treated seroconverters and long-term non-progressors.

2010

Kinloch, S. (2010). HIV-1 specific T cells during prolonged antiretroviral treatment in HIV-1 seroconverters.
Cellerai, C., Harari, A., Yerly, S., Byrne, P., Carroll, A., Stauss, H., ...Kinloch, S. (2010). Immunological and virological comparison between long-term ART-Treated HIV-1 seroconverters and long-term non progressors - abstract.
Fryer, H.R., Frater, J., Duda, A., Roberts, M.G., SPARTAC Trial, I.n.v.e.s.t.i.g.a.t.o.r.s., Phillips, R.E., ...Kinloch, S. (2010). Modelling the evolution and spread of HIV immune escape mutants. PLoS Pathogens, 6 (11), doi:10.1371/journal.ppat.1001196
Kinloch, S. (2010). T cell analysis in long-term treated sero-converters.
Kinloch, S. (2010). When to Start ART: The Case for Starting Earlier.

2009

Stratton, R., Slapak, G., Mahungu, T., Kinloch-de Loes, S. (2009). Autoimmunity and HIV. Current Opinion in Infectious Diseases, 22 49-56.
Kinloch, S. (2009). Aviremia after discontinuation of prolonged antiretroviral therapy initiated during primary HIV-1 infection.
Kinloch, S., Cellerai, C., Yerly, S., Byrne, P., Carroll, A., Stauss, H., ...Pantaleo, G. (2009). Immunologic and virologic characterization of an ART-treated HIV-1 patient cohort with long-term control of viremia - abstract.
Kinloch, S., Cellerai, C., Yerly, S., Byrne, P., Carroll, A., Stauss, H., ...Pantaleo, G. (2009). Immunologic and virologic characterization of an ART-treated HIV-I patients cohort with long-term control of viremia. RETROVIROLOGY, 6 doi:10.1186/1742-4690-6-S3-P277
Barqasho, B., Nowak, P., Tjernlund, A., Kinloch, S., Thorborn, D., Perrin, L., ...Sonnerborg, A. (2009). Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. HIV Medicine, 10 (2), 94-102.
Barqasho, B., Nowak, P., Tjernlund, A., Kinloch, S., Goh, L.-.E., Lampe, F., ...QUEST study, g.r.o.u.p. (2009). Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption.. HIV MEDICINE, 10 (2), 94-102. doi:10.1111/j.1468-1293.2008.00657.x
Cellerai, C., Harari, A., Stratton, R., Mahungu, T., Stauss, H., Johnson, M., ...Kinloch, S. (2009). Polyfunctional HIV-1 specific T cell responses are detectable during treatment with mycophenolic mofetil (MMF) in a SLE patient with HIV-1 infection - abstract.
Kinloch, S. (2009). Primary HIV infection, today and tomorrow.
Bergroth, T., Ekici, H., Gisslén, M., Kinloch, S., Goh, L.E., Freedman, A., ...Sönnerborg, A. (2009). Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naive patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. J Med Virol, 81 (1), 1-8.
Bergroth, T., Ekici, H., Gisslen, M., Kinloch-de Loes, S., Goh, L.-.E., Freedman, A., ...Sonnerborg, A. (2009). Selection of Drug-Resistant HIV-1 During the Early Phase of Viral Decay Is Uncommon in Treatment-Naive Patients Initiated on a Three- or Four-Drug Antiretroviral Regimen Including Lamivudine. JOURNAL OF MEDICAL VIROLOGY, 81 (1), 1-8. doi:10.1002/jmv.21363

2008

Maniar, A.J., Maniar, J.K., Kamath, R., Shah, S., Verma, R., Kinloch, S. (2008). Primary HIV-1 infection - a "window of opportunity" for healthcare providers. Journal of the Association of Physicians of India, 56 628-632.
Cellerai, C., Little, S., Kinloch-de Loes, S. (2008). Treament of acute HIV-1 infection: are we getting there?. Current Opinion in HIV/AIDS, 3 67-74.

2007

Kinloch, S. (2007). Clinical and Treatment aspects of primary HIV infection.
Kinloch-de Loes, S. (2007). Controversies in the treatment of HIV-1 infection.. Infections in Medicine, 24 335-338.
Nilsson, J., Kinloch-de Loes, S., Granath, A., Sonnerborg, A., Goh, L.E., Andersson, J. (2007). Early immune activation in gut-associated lymphoid tissue during acute HIV infection. AIDS, 21 565-574.
Lampe, F.C., Porter, K., Kaldor, J., Law, M., Kinloch-de Loes, S., Phillips, A.N., CASCADE, C.o.l.l.a.b.o.r.a.t.i.o.n. (2007). Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antiviral Therapy, 12 (2), 189-193.
Samri, A., Lampe, F., Autran, B., Phillips, A.N., Goh, L., El Habib, R., ...the QUEST Core and Study, G.r.o.u.p. (2007). Multifunctional HIV-1 specific CD4 and CD8 T cell responses during a therapeutic immunization study (QUEST) in HAART-Treated acutely-infected (PHI) subjects - abstract H-116.
Hoen, B., Cooper, D.A., Lampe, F., Perrin, L., Clumeck, N., Phillips, A.N., ...Gazzard, B. (2007). Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clinical Infectious Diseases, 45 (3), 381-390. doi:10.1086/519428
Breen, R.A., Hardy, G.A., Perrin, F.M., Lear, S., Kinloch, S., Smith, C.J., ...Lipman, M.C. (2007). Rapid diagnosis of smear-negative tuberculosis using immunology and microbiology with induced sputum in HIV-infected and uninfected individuals. PLoS ONE, 2 (12), e1335-.
Kinloch, S. (2007). Second-line therapy.
Kinloch, S. (2007). Second-line therapy.
Lampe, F.C., Smith, C.J., Madge, S., Kinloch-de Loes, S., Tyrer, M., Sabin, C.A., ...Phillips, A.N. (2007). Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Archives of Internal Medicine, 167 (7), 692-700. doi:10.1001/archinte.167.7.692

2006

Kinloch, S. (2006). Acute HIV-1 infection. [Abstract 23].
Tjernlund, A., Barqasho, B., Nowak, P., Kinloch, S., Thorborn, D., Perrin, L., ...Andersson, J. (2006). Early induction of leukemia inhibitor factor (LIF) in acute HIV-1 infection.. AIDS, 20 11-19.
Mahungu, T., Kinloch, S., Brough, G., Stratton, R., Johnson, M.A. (2006). HIV and systemic lupus erythematosus (SLE) - abstract.
Kinloch, S. (2006). Immunomodulators and vaccines.
Kinloch, S., Lampe, F.C., Perrin, L., Cooper, D., Hoen, B., Goh, L.E., ...Tsoukas, C. (2006). QUEST Study: Follow-up at one year post-stopping treatment in primary HIV Infection (PHI) subjects on long-term ART randomized to therapeutic immunization versus placebo - Abstract H-116.
Kinloch, S. (2006). The QUEST study.
Kinloch, S. (2006). The Quest study, from a clinician with immunological inclination.. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 42 S15-S16.
Autran, B., Kinloch-de Loes, S., Katlama, C. (2006). Therapeutic immunization in HIV infection. Current Opinion in HIV/AIDS, 1 323-329.
Kinloch- de Loes, S. (2006). Treatment of acute HIV-1 infection: is it coming of age?. The Journal of Infectious Diseases, 194 721-724.

2005

Kinloch-de Loes, S., Hoen, B., Smith, D.E., Autran, B., Lampe, F.C., Phillips, A.N., ...Sonnerborg, A. (2005). Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. The Journal of Infectious Diseases, 192 (4), 607-617.
Girardi, E., Sabin, C.A., d'Arminio Monforte, A., Hogg, B., Phillips, A.N., Gill, M.J., ...Bernasconi, E. (2005). Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases, 41 (12), 1772-1782.
Kinloch, S. (2005). Lessons learnt from therapeutic immunisation in HIV seroconverters. [Abstract 87].
Herzmann, C., Kinloch, S., Johnson, M. (2005). Rash in an HIV-positive patient. HIV MEDICINE, 6 (6), 379. doi:10.1111/j.1468-1293.2005.00329.x
Herzmann, C., Kinloch, S., Johnson, M. (2005). Rash in an HIV-postive patient. Atazanavir.. HIV Medicine, 6 379-.
Samri, A., Lampe, F., Kinloch, S., Phillips, A.N., Perrin, L., Cooper, D., ...Sonnerborg, A. (2005). Relative effects of therapeutic immunisation and discontinuation of ART on HIV-1 specific CD4 and CD8 T cells producing interferon-gamma (IFN-) in ART-treated acutely-infected (PHI) subjects (QUEST Study) - abstract.

2004

Kinloch, S., Perrin, L., Hoen, B., Lampe, F., Phillips, A.N., Goh, L., ...El Habib, R. (2004). Evaluation of two therapeutic HIV vaccination regimens in HAART-treated primary HIV infection (PHI) subjects following analytical treatment interruption: results of a randomised, double-blind, placebo-controlled study (QUEST PROB 3005). [abstract 168].
Smith, C.J., Sabin, C.A., Youle, M.S., Kinloch-de Loes, S., Lampe, F.C., Madge, S., ...Phillips, A.N. (2004). Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. The Journal of Infectious Diseases, 190 (10), 1860-1868. doi:10.1086/425075
Kinloch-de Loes, S. (2004). Role of therapeutic vaccines in HIV-1.. Journal of Antimicrobial Chemotherapy, 53 562-566.
Kinloch-de Loes, S. (2004). Role of therapeutic vaccines in the control of HIV-1. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 53 (4), 562-566. doi:10.1093/jac/dkh132
Kinloch, S. (2004). The role of therapeutic vaccination.
Kinloch, S. (2004). Will therapeutic vaccines work?.

2003

Lampe, F.C., Smith, D., Cooper, D., Perrin, L., Hoen, B., Girard, P.M., ...Battegay, M. (2003). Adherence to HAART during primary HIV infection (PHI): association with treatment cessation and virological suppression - abstract.
Smith, C.J., Sabin, C.A., Lampe, F.C., Kinloch-de-Loes, S., Gumley, H., Carroll, A., ...Phillips, A.N. (2003). The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS, 17 (7), 963-969. doi:10.1097/00002030-200305020-00004
Cozzi-Lepri, A., Kinloch, S., Arici, C., Phillips, A.N., Santoro, D., Narciso, P., ...for the I.Co.N.A. Study, g.r.o.u.p. (2003). The pre-therapy CD4 count and the duration of safe HAART interruption in patients who discontinue all their drugs with a CD4 count >200 cells/ul - abstract.
Kinloch, S., Cooper, D., Lampe, F., Smith, D., Janossy, G., Hoen, B., ...Goh, L.E. (2003). The QUEST cohort: Treatment of primary HIV infection with quadruple HAART: Week 48 preliminary results - Abstract 520.
Kinloch, S. (2003). The QUEST Trial. “Immune reconstitution & control of HIV”.
Kinloch, S. (2003). The role of early treatment for HIV.
Kinloch, S., McRae, E., Johnson, M.A., Loveday, C. (2003). Transmission of NNRTI resistance among two patients with recent HIV infection - abstract.

2002

Goh, L.E., Bernard, F., Lampe, F., Janossy, G., Cooper, D., Cunningham, P., ...Perrin, L. (2002). Cytomegalovirus infection/reactivation in primary HIV-1 infection is associated with an increase in CD8/CD38 and a delayed virological response to HAART - abstract.
Kinloch, S.A., B. (2002). HIV-1 therapeutic vaccines. Journal of INfection, 44 152-159.
Phillips, A.N., Staszewski, S., Lampe, F., Youle, M.S., Klauke, S., Bickel, M., ...Loveday, C. (2002). Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. The Journal of Infectious Diseases, 186 (8), 1086-1091.
Goh, L.E., Bernard, M., Lampe, F., Janossy, G., Cooper, D., Cunningham, P., ...Mc Dade, H. (2002). Impact of primary CMV infection or reactivation on HIV and immunological parameters in patients with primary HIV infection (PHI) - abstract.
Andersson, J., Kinloch, S., Sonnerborg, A., Nilsson, J., Fehniger, T.E., Spetz, A.L., ...Gazzard, B. (2002). Low levels of perforin in CD8+ T lymphocytes in lymphoid tissue during acute human immunodeficiency virus type 1 infection.. The Journal of Infectious Diseases, 185 1355-1358.
Tilling, R., Kinloch, S., Goh, L.E., Cooper, D., Perrin, L., Lampe, F., ...Andersson, J. (2002). Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS, 16 (4), 589-596.
Lampe, F.C., Johnson, M.A., Loveday, C., Chaloner, C., Sabin, C.A., Youle, M., ...Phillips, A.N. (2002). Recent trends in treatment use and virological suppression in a London clinic population - abstract.
Kinloch, S., Lampe, F., Janossy, G., Phillips, A., Cooper, D., Perrin, L., ...Goh, L.E. (2002). Simplification to triple HAART after achieving viral suppression with quadruple HAART initiated at the time of primary HIV infection (PHI) is not associated with increased low-level viral rebound in the QUEST Protocol [Poster ThPeB7207].
Perrin, L., Cooper, D.A., Hoen, B., Kinloch, S., Phillips, A., Tsoukas, C., ...Janossy, G. (2002). Therapeutic vaccination in primary HIV infection, the Quest trial. Vaccine, 20 (15), 2004-2006. doi:10.1016/S0264-410X(02)00087-7

2001

Tenner-Racz, K., Perrin, L., Stellbrink, H.J., Kinloch, S. (2001). Low lymph node viral load despite high viremia in seroconverters supports early HAART intervention [Abstract 758].
Goh, L.E., Perrin, L., Hoen, B., Cooper, D., Phillips, A., Janossy, G., ...Kinloch, S.Q.U.E.S.T.S.G. (2001). Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: The QUEST study. HIV Clinical Trials, 2 (5), 438-444.

2000

Perrin, L., Cooper, D., Kinloch, S., Janossy, G., Gazzard, B., Phillips, A., ...Lindback, S. (2000). Baseline mRNA levels are the only independent virological marker of viral suppression.
Janossy, G., Tilling, R., Turnbull, W., Phillips, A.N., Cooper, D., Hoen, B., ...Kinloch, S. (2000). CD38++/CD8 T cell subsets: a key marker to monitor responses of primary HIV infection (PHI) patients receiving HAART - abstract.
Janossy, G., Tilling, R., Kinloch, S., Turnbull, W., Phillips, A.N., Cooper, D., ...Perrin, L. (2000). CD38++/CD8 T cell subsets: a key marker to monitor responses of primary HIV infection patients receiving HAART.
Vernazza, P., Perrin, L., Vora, S., Cooper, D., Bloch, M., Finlaysson, R., ...Tyrer, M. (2000). Cell- associated HIV DNA in semen is low during early stages of primary HIV infection and is efficiently suppressed with HAART.
Dann, L.C., Loveday, C., Allison, S., Kinloch, S., Johnson, M. (2000). Frequency of mutations associated with antiretroviral drug resistance in patients undergoing primary HIV-1 infection (PHI). AIDS, 14 S122.
Mocroft, A., Devereux, H., Kinloch-de-Loes, S., Wilson, D., Madge, S., Youle, M., ...Johnson, M.A. (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS, 14 (11), 1545-1552. doi:10.1097/00002030-200007280-00010
Mocroft, A., Devereux, H., Kinloch-de-Loes, S., Wilson, D., Madge, S., Youle, M., ...Johnson, M.A. (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS, 14 (11), 1545-1552.
Vernazza, P., Perrin, L., Vora, S., Cooper, D., Bloch, M., Finlaysson, R., ...Tyrer, M. (2000). Increased seminal shedding of HIV during primary infection augments the need for early diagnosis and prevention - abstract.
Cooper, D.A., Perrin, L., Kinloch, S., Janossy, G., Gazzard, B., Phillips, A.N., ...Lindback, S. (2000). Intervention with quadruple HAART (Combivir (COM)-abacavir-(ABC)-amprenavir (APV)) during primary HIV infection (PHI) is associated with rapid viremia clearance and decrease of immune activation - abstract.
Lampe, F.C., Phillips, A.N., Kinloch, S., Johnson, M.A., Goh, L., Hawkins, D., ...Freedman, A. (2000). Quadruple HAART in primary HIV infection: Results from QUEST.
Goh, L.E., McDade, H., Kinloch, S., Perrin, L., Cooper, D., Phillips, A., ...Tsoukas, C. (2000). The QUEST trial, a paradigm of HIV collaborative research. Nature Medicine, 6 (11), 1194-.
Tenner-Racz, K., Racz, P., Stellbrink, H.J., Kinloch, S., Youle, M., Gazzard, B., ...Staszewski, S. (2000). Unexpected low levels of HIV-1 replication in the lymph nodes of seroconverters supports early HAART - abstract.

1999

King, D.S., Amjadi, P., Tilling, R.S., Kinloch-de Loes, S., Loveday, C., Johnson, M.A., ...Sciard, E.-.L. (1999). "Naive" and "memory" CD4+ T cells and T-cell receptor (TCR) Vbeta repertoire dynamics are independent of the levels of viremia following HIV seroconversion.. Immunological Letters, 66 199-206.
Vanhems, P., Dassa, C., Lambert, J., Cooper, D.A., Perrin, L., Vizzard, J., ...Allard, R. (1999). Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 21 99-106.
Andersson, J., Racz, P., Tenner-Racz, K., Stellbrink, H.J., Kinloch, S., Janossy, G., ...Bloch, M. (1999). Defect in cytolytic effector molecules in lymphoid tissue during primary HIV infection (PHI) is a very early mechanism of immune dysfunction.
Kinloch, S. (1999). Early intervention including seroconversion and during primary HIV infection.
Huckett, L., Devereux, H., Kinloch, S., Johnson, M., Loveday, C. (1999). Genetic diversification of HIV-1 in two patients infected by a common source and following onset of HAART - abstract.
Kinloch, S., Janossy, G., Phillips, A., Perrin, L., Hoen, B., Cooper, D., ...McDade, H. (1999). HAART (3TC/ZDV/abacavir/Amprenavir) during primary HIV infection (PHI) is associated with a sharp viremia decline and increase in IL-2 synthetic capacity.
Vernazza, P., Perrin, L., Cooper, D., Bloch, M., Finlayson, R., Gazzard, B., ...Goh, L. (1999). High genital shedding of HIV during primary HIV infection (PHI) supports the need for early recognition and intervention - abstract.
Vernazza, P.L., Perrin, L., Cooper, M., Bloch, R., Finlayson, R., Gazzard, B., ...Stasweski, S. (1999). High viral burden in semen during primary HIV infection (PHI) augments the need for earlier diagnosis and intervention - abstract.
Racz, P., Tenner-Racz, K., Andersson, J., Gazzard, B., Kinloch, S., Stellbrink, H., ...Goh, L. (1999). HIV-1 associated lymph node changes during primary HIV infection (PHI).
Andersson, J., Nilsson, J., Perrin, L., Kinloch, S., Tyrer, M., Gazzard, B., ...Finlayson, R. (1999). Imbalance of cytokine effector molecules in CD8+ in lymphoid tissue during primary HIV infection (PHI).
Madge, S., Kinloch-de Loes, S., Mercey, D., Johnson, M.A., Weller, I. (1999). Lipodystrophy in patients naive to HIV protease inhibitors. AIDS, 13 (6), 735-737. doi:10.1097/00002030-199904160-00020
Madge, S., Kinloch, S., Tyrer, M., Johnson, M.A. (1999). Lypodystrophy syndrome in patients on reverse transcriptase inhibitors - abstract.
King, D.J.S., Amjadi, P., Tilling, R., Kinloch-de-Loes, S., Loveday, C., Johnson, M.A., ...Larsson-Schiad, E.L. (1999). Naive and memory CD4+ T cells and T cell receptor (TCR) V-beta repertoire dynamics are independent of the levels of viremia following HIV seroconversion. Immunology Letters, 66 199-206.
Kinloch, S., Phillips, A., Cooper, D., Perrin, L., Tilling, R., Turnbull, W., ...Janossy, G. (1999). Parallel decrease of CD38++ CD8 cells and viremia in primary HIV infection (PHI) patients on quadruple HAART (ZDV/3TC/Abacavir/Amprenavir) - abstract.
Andersson, J., Racz, P., Tenner-Racz, K., Stellbrink, H.J., Kinloch, S., Janossy, G., ...Bloch, M. (1999). Potent and aberrant CD4 responses in lymphoid tissue during primary HIV infection.
Hoen, B., Kinloch, S., Janossy, G., Cooper, D., Phillips, A., Perrin, L., ...Goh, L. (1999). Preliminary results: Quadruple HAART (ZDV/3TC/Abacavir/Amprenavir) initiated during primary HIV infection (PHI) is associated with a sharp viremia decrease and increase in CD4 response.
Kinloch, S., Tilling, R., Sabin, C., Tyrer, M., Madge, S., Turnbull, W., ...Janossy, G. (1999). Primed and unprimed CD4 and CD8 subsets during untreated primary HIV infection (PHI) and very early infection (VEI) - abstract.
Mocroft, A., Devereux, H., Kinloch, S., Wilson, D., Madge, S., Youle, M., ...Johnson, M.A. (1999). Response to HAART among 518 patients from a single treatment centre - abstract.
Mocroft, A., Barry, S., Sabin, C.A., Cozzi-Lepri, A., Kinloch, S., Drinkwater, A., ...Phillips, A.N. (1999). The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. 13 (10), 1255-1261.

1998

Tilling, R.S., Kinloch, S., Turnbull, W., Tyrer, M., Johnson, M.A., Janossy, G. (1998). Absolute interleukin-2 (IL-2) and interferon-gamma synthesis in peripheral blood of HIV-infected patients during primary HIV infection (PHI) - abstract.
Kinloch, S., Goh, L., Perrin, L., Cooper, D., Tsoukas, C., Hoen, B., Gaines, H. (1998). Can durable viral suppression in patients with primary HIV infection using HAART lead to HIV eradication? - abstract.
Kinloch, S., Tilling, R.S., Loveday, C., Johnson, M.A., Janossy, G. (1998). CD38 expression on CD8+ T cells during primary HIV infection - abstract.
Larsson-Sciard, E.L., King, D., Tarragona, A., Kinloch, S., Janossy, G., Gotch, F. (1998). Dynamics of CD8+ T cell receptor V gene usage before and after retroviral therapy in primary HIV infection - abstract.
Huckett, L., Devereux, H., Loveday, C., Kinloch, S., Janossy, G. (1998). Investigation of HIV-1 evolution following early therapy in patients with primary HIV-1 infection.
Kinloch, S., Tilling, R.S., Turnbull, W., Tyrer, M., Johnson, M.A., Janossy, G. (1998). Naïve T cell subsets during acute infection (AI) with HIV and response to highly active anti-retroviral therapy - abstract.
Vanhems, P., Lambert, J., Cooper, D.A., Hirschel, B., Vizzard, J., Kinloch-de, L., ......R. (1998). Severity and prognosis of acute HIV-1 illness-a dose response relationship.. Clinical Infectious Diseases, 26 323-329.
Vanhems, P., Lambert, J., Cooper, D.A., Perrin, L., Carr, A., Hirschel, B., ...Allard, R. (1998). Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 (2), 323-329. doi:10.1086/516289
Yerly, S., Rakik, A., Kinloch-de Loes, S., Hirschel, B., Descamps, D., Brun-Vezinet, F., Perrin, L. (1998). Switch to an unusual amino acid at codon 215 of the HIV-1 reverse transcriptase gene in seroconverters infected with zidovudine resistant variants.. Journal of Virology, 72 3520-3523.
Kinloch, S., Tilling, R., Johnson, M.A., Tyrer, M., Loveday, C., Griffiths, P., Janossy, G. (1998). Viro-immunological monitoring at the time of primary HIV infection (PHI) and during HAART of two patients near-simultaneously (N-S) infected with HIV - abstract.

1997

Vanhems, P., Lambert, J., Cooper, D.A., Hirschel, B., Carr, A., Perrin, L., ...Allard, R. (1997). Acute HIV-1 illness severity and prognosis: a dose-dependent response relationship - abstract.
Vanhems, P., Allard, R., Cooper, D.A., Perrin, L., Kinloch-de Loes, S., Carr, A., ......S. (1997). Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive?. Clinical Infectious Diseases, 24 965-970.
Kinloch-de Loes, S., Perneger, T.V. (1997). Follow-up of patients with primary HIV infection initially treated with zidovudine or placebo. Journal of Infection, 35 111-116.
Janossy, G., Tilling, R.S., Turnbull, W., Bofill, M., Johnson, M.A., Cosarizza, A., Kinloch, S. (1997). Immune activation markers in patients with primary HIV infection (PHI) or early HIV seroconversion - abstract.
Janossy, G., Kinloch-de Loes, S. (1997). Immune reconstitution in HIV infection. Journal of Combination Therapy, 2 70-74.
Tilling, R.S., Kinloch, S., Johnson, M.A., Janossy, G. (1997). Normalisation of IL-2 and interferon-gamma synthesis in naïve and memory T cells in primary HIV infection (PHI) after early triple combination therapy - abstract.
Kinloch, S. (1997). Primary HIV Infection.
Tilling, R.S., Kinloch, S., Johnson, M.A., Janossy, G. (1997). Primary HIV infection (PHI) and CD4 IL-2 synthetic capacity - abstract.
Kinloch-de Loës, S., Perneger, T.V. (1997). Primary HIV infection: follow-up of patients initially randomized to zidovudine or placebo.. The Journal of infection, 35 (2), 111-116. doi:10.1016/s0163-4453(97)91413-4

1996

Yerly, S., Rakik, A., Kinloch-de-Loes, S., Erb, P., Vernazza, P., Hirschel, B., Perrin, L. (1996). [Prevalence of transmission of zidovudine-resistant viruses in Switzerland. l'Etude suisse de cohorte VIH].. Schweizerische medizinische Wochenschrift, 126 (43), 1845-1848.
Perrin, L., Yerly, S., Kinloch, S., Rutschmann, O., Figueras, G., Pechère, M., Hirschel, B. (1996). Combined therapy in primary HIV infection - abstract.
Perrin, L., Rakik, A., Yerly, S., Baumberger, C., Kinloch-de Loes, S., Figueras, G., ...Hirschel, B. (1996). Combined therapy with zidovudine and L-697-661 in primary HIV infection. AIDS, 10 1233-1237.
Kinloch-de-Loës, S., Perrin, L.H., Hirschel, B.J., Perneger, T.V. (1996). Controversies: does the CD4+ cell count reflect clinical efficacy?. JAMA, 276 (15), 1219-. doi:10.1001/jama.276.15.1219
Kinloch-de Loes, S., Perrin, L., Hirschel, B., Pernegger, T.V. (1996). Does the CD4+ cell count affect clinical efficacy?. JAMA, 276 1219-1220.
Kinloch, S., Perrin, L., Hirschel, B. (1996). Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. New England Journal of Medicine, 334 992-.
Yerly, S., Rakik, A., Kinloch, S., Hirschel, B., Perrin, L. (1996). Persistence of zidovudine resistance mutations in patients with primary HIV infection - abstract.
Yerly, S., Rakik, A., Kinloch-de Loes, S., Erb, P., Vernazza, P., Hirschel, B., Perrin, L. (1996). Prevalence de la transmission de virus resistant a la zidovudine en Suisse. Schweizerische Medizinische Wochenschrift, 126 1845-1848.
Jolles, S., Kinloch-de Loes, S., Johnson, M.A., Janossy, G.P.H.I.A.N.M.E. (1996). Primary HIV-1 infection: a new medical emergency?. BMJ (Clinical Research Ed.), 312 1243-1244.
Kinloch, S. (1996). Studies in primary HIV infection.
Kinloch, S., Perrin, L., Hirschel, B. (1996). The rise of HIV transmission by screened blood. NEW ENGLAND JOURNAL OF MEDICINE, 334 (15), 992.
Kinloch, S., Perrin, L., Hirschel, B. (1996). The risk of HIV transmission by screened blood.. The New England journal of medicine, 334 (15), 992-. doi:10.1056/nejm199604113341516

1995

Kinloch-de Loes, S., Hirschel, B.J., Hoen, B., Cooper, D.A., Tindall, B., Carr, A., ...Mathiesen, L. (1995). A controlled trial of zidovudine in primary human immunodeficiency virus infection. New England Journal of Medicine, 333 408-413.
Kinloch, S., Perrin, L., Hirschel, B. (1995). Early treatment of HIV infection. New England Journal of Medicine, 333 1783-.
Galetto-Lacour, A., Kinloch-de Loes, S., Hirschel, B., Perrin, L. (1995). Primary HIV infection: an often suspected diagnosis but confirmed late. Schweizerische Medizinische Wochenschrift, 125 (8), 341-346.
Kinloch, S. (1995). Primary HIV-1 infection: diagnosis and treatment.
Perrin, L., Kinloch-de Loes, S. (1995). Therapeutic interventions in primary HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10(suppl) S69-S76.
Perrin, L., Yerly, S., Rakik, A., Kinloch, S., Hirschel, B. (1995). Transmission of 215 mutants in primary HIV infection and analysis after 6 months of zidovudine.
Kinloch, S. (1995). Treatment of primary HIV infection. Comprehensive Management of HIV Disease.

1994

Omarini, L.P.A., Kinloch-de Loes, S., Garcia, J., Lew, D., Kurt, A.M., Saurat, J.H. (1994). Bacillary angiomatosis of the calcaneum. A case report.. Skeletal Radiology, 23 478-481.
Kinloch, S., Yerly, S., Hirschel, B., Perrin, L. (1994). Markers of early occurrence of opportunistic infections in patients with primary HIV infection - abstract.
Kinloch, S., Hoen, B., Cooper, D., de Witt, S., Novati, R., Mathiesen, L., ...Iten, A. (1994). Zidovudine versus placebo in primary HIV infection (PHI).
Hirschel, B., Kinloch, S., Hoen, B., Cooper, D., Lazzarin, A., Clumeck, N., ...the Swiss HIV, C.o.h.o.r.t. (1994). Zidovudine versus placebo: a European-Australian collaborative study.
Perrin, L., Kinloch, S., Hoen, B., Cooper, D., Tindall, B., de Witt, S., ...van Overbeck, J. (1994). Zidovudine versus placebo: a European-Australian collaborative study.

1993

Baumberger, C., Kinloch, S., Yerly, S., Hirschel, B., Tindall, B., Perrin, L. (1993). Circulating HIV RNA virus and provirus in primary HIV infection (PHI) - abstract.
Baumberger, C., Kinloch, S., Yerly, S., Hirschel, B., Tindall, B., Perrin, L. (1993). Circulating HIV RNA virus and provirus in primary HIV infection (PHI) - abstract.
Baumberger, C., Kinloch-de Loes, S., Hirschel, B., Perrin, L. (1993). High levels of circulating RNA in patients with symptomatic HIV-1 infection.. AIDS, 7 S59-S64.
COOK, J.K.A., KINLOCH, S., ELLIS, M.M. (1993). INVITRO AND INVIVO STUDIES IN CHICKENS AND TURKEYS ON STRAINS OF TURKEY RHINOTRACHEITIS VIRUS ISOLATED FROM THE 2 SPECIES. AVIAN PATHOLOGY, 22 (1), 157-170. doi:10.1080/03079459308418907
Kinloch, S. (1993). Presentation cutanee. In Hirschel, B. (Ed.), Le Sida. Guide du praticien.Diagnostic et traitement, prise en charge.. Editions Medecine et Hygiene.
Kinloch, S. (1993). Primo-infections à VIH.
Kinloch-de Loes, S., de Saussure, P., Saurat, J.H., Stalder, H., Hirschel, B., Perrin, L.H. (1993). Symptomatic primary HIV infection due to human immunodeficiency virus type 1:review of 31 cases. Clinical Infectious Diseases, 17 59-63.
Kinloch, S., Hirschel, B., Hoen, B., Tindall, B., Perrin, L. (1993). Zidovudine treatment versus placebo in primary HIV infection: preliminary results - abstract.

1992

Kinloch-de Loës, S., Masouyé, I., Salomon, D., Harms, M., Chamot, E., Louis, O., Saurat, J.H. (1992). [Bacillary angiomatosis: apropos of a case].. Schweizerische medizinische Wochenschrift, 122 (31-32), 1168-1172.
Kinloch, S., Yerly, S., Perrin, L., Hirschel, B., Clumeck, N., Canton, P., ...Tindall, B. (1992). A prospective, randomised, placebo-controlled study of the treatment of primary HIV infection with zidovudine.
Kinloch, S., Peclard, N., Hirschel, B., Lew, D., Saurat, J.H. (1992). Acute osteitis in bacillary angiomatosis - abstract.
Kinloch-de Loes, S., Masouye, I., Salomon, D., Harms, M., Chamot, E., Louis, O., Saurat, J.H. (1992). Angiomatose bacillaire: a propos d'un cas. Schweizerische Medizinische Wochenschrift, 122 1168-1172.
Weber, R., Ledergerber, B., Kinloch, S., Chave, J.P., Brungger, H., Opravil, M., ...the research group of the Swiss HIV Cohort, S.t.u.d.y. (1992). Association of oesophageal candidiasis with acute HIV infection and the value of oesophageal candidiasis as a diagnostic criterion for AIDS - abstract.
Rieckhoff-Cantoni, L., Bernard, P., Didierjean, L., Imhof, K., Kinloch-de Loes, S., Saurat, J.H.K., S. (1992). Frequency of bullous pemphigoid-like antibodies as detected by western immunoblot analysis in pruritic dermatoses. Archives of Dermatology, 128 791-794.
Kinloch, S., de Saussure, P., Vanhems, P., Hirschel, B., Perrin, L. (1992). Primary HIV infection: a prospective and retrospective study - abstract.

1991

Kinloch-de Loes, S., Didierjean, L., Rieckhoff-Cantoni, L., Imhof, K., Perrin, L., Saurat, J.H. (1991). Bullous pemphigoid autoantibodies,HIV-1 infection and pruritic papular eruption. AIDS, 5 451-455.
Baumann, R., Tauber, M.G., Opravil, M., Hirschel, B., Kinloch, S., Chave, J.P., ...Luthy, R. (1991). Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi's sarcoma.. Klinische Wochenschrift, 69 360-367.
Harms, M., Kinloch, S.S., J, H. (1991). Kaposi's Sarcoma + HIV infection = AIDS?. Dermatologica, (82), 66-.
Kinloch, S. (1991). Presentation cutanee. In Pechere, J.C., Acar, J., Armengaud, M., Grenier, B., Moellering Jr, R., Sande, M., ...Zinner, S. (Eds.), Les Infections. Edisem.
Calza, A.M., Kinloch, S., Mainetti, C., Salomon, D., Saurat, J.H. (1991). Primary human immunodeficiency virus infection mimicking syphilis. The Journal of Infectious Diseases, 164 615-616.
Kinloch, S., Calza, A.M., Mainetti, C., Schmied, E., Saurat, J.H. (1991). Primo-infections à VIH (Primary HIV infection).
Zuber, H., Kinloch, S., Yerly, S., Perrin, L.H., Saurat, J.H. (1991). Sexually transmitted diseases and HIV detection by the polymerase chain reaction - abstract.
Kinloch, S., Germann, D., Zurn, A., Saurat, J.H. (1991). Topical foscarnet in herpes simplex infection - abstract.

1990

Didierjean, L., Kinloch, S., Rieckhoff, L., Imhof, K., Perrin, L., Saurat, J.H. (1990). Bullous pemphigoid autoantibodies, HIV-1 infection and pruritic papular skin eruption.

1989

Kinloch, S. (1989). Autoanticorps de type pemphigoïde bulleuse chez les patients HIV positifs.
Kinloch, S., Didierjean, L., Saurat, J.H. (1989). Bullous pemphigoid (BP) type antibodies in HIV-infected patients - abstract.
Kinloch, S., Bouvier, M., Lucas, S., Cox, J. (1989). Myospherulosis:an iatrogenic complication of antisyphilitic treatment?. The Journal of Infectious Diseases, 160 913-914.

1988

Kinloch-de Loës, S., Radeff, B., Saurat, J.H. (1988). AIDS meets syphilis: changing patterns of the syphilitic infection and its treatment.. Dermatologica, 177 (5), 261-264. doi:10.1159/000248576
Kinloch, S., Radeff, B., Saurat, J.H. (1988). Syphilis and HIV. Dermatologica, 177 261-264.